Imaging, Digital, Angiography Symposium 1

Related

• 

  Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial

  Eric W Schneider, MD

  Annual Meeting Talks

  2023

• 

  Six Monthly Intravitreal Aflibercept to Improve Macular Perfusion in Diabetic Retinopathy Without Macular Edema

  Yoon Jeon Kim, MD

  Annual Meeting Talks

  2023

• 

  Anti-VEGF Injections and Risk of Traction Retinal Detachments in Eyes With Proliferative Diabetic Retinopathy: Pooled Analysis of 5 DRCR.net Trials

  Hani Salehi-Had, MD, FASRS

  Updates from the Field